New antirheumatic drugs: Any real added value? A critical overview of regulatory criteria for their marketing approval

European Journal of Clinical Pharmacology

Volumn 63, Issue 9, 2007, Pages 879-889

  Bertele', Vittorio ^a   Assisi, Alessandro ^a   Di Muzio, Valeria ^a   Renzo, Danila ^a   Garattini, Silvio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

ACR; Adalimumab; Anakinra; Etanercept; Infliximab; Leflunomide; Methotrexate; Radiographic progression; Rheumatoid arthritis; Signs and symptoms

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NEW DRUG; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ANAPHYLAXIS; APLASTIC ANEMIA; ARTICLE; BLOOD DYSCRASIA; BLOOD PRESSURE MEASUREMENT; BRONCHITIS; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DEMYELINATING DISEASE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INFORMATION; HEART FAILURE; HUMAN; INFECTION; JOINT RADIOGRAPHY; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LUNG EDEMA; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; MONOTHERAPY; PANCREATITIS; PANCYTOPENIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; SKIN INFECTION; STEVENS JOHNSON SYNDROME; THERAPY EFFECT; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; HUMANS; IMMUNOGLOBULIN G; ISOXAZOLES; ITALY; LEGISLATION, DRUG; MARKETING; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS;

EID: 34547800234     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0338-9     Document Type: Article

References (41)

1. Furst DE (2004) Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 26(12):1960-1975
2. Moore RA, Derry S, Makinson GT, McQuay HJ (2005) Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 7(3):R644-R665
3. Mobley JL (2006) Using epidemiology and archaeology to unearth new drug targets for rheumatoid arthritis therapy. Drug Discov Today 11(1-2):4-7
4. Alamanos Y, Drosos AA (2005) Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4(3):130-136
5. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G (2005) TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 4(3):153-161
6. Lewis C (2000) Arthritis. Timely treatments for an ageless disease. FDA Consum 34(3):27-29, 31-33.
7. Konttinen YT, Seitsalo S, Lehto M, Santavirta S (2005) Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs. Acta Orthop 76(5):614-619
8. Weaver AL (2004) The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology 43[Suppl 3]:iii17-iii23
9. Afeltra A (2001) Treatment of rheumatoid arthritis: new therapeutic approaches with biological agents. Curr Drug Targets Immune Endocr Metabol Disord 1(1):45-65
10. Genovese MC (2005) Biologic therapies in clinical development for the treatment of rheumatoid arthritis. J Clin Rheumatol 11[Suppl 3]:S45-S54
11. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353(9149):259-266
12. http://www.emea.europa.eu/humandocs/Humans/EPAR/arava/arava.htm.
13. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK et al (2001) Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 60(10):913-923
14. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39(6):655-665
15. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159(21):2542-2550
16. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932-1939
17. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594-1602
18. http://www.emea.europa.eu/humandocs/Humans/EPAR/remicade/remicade.htm.
19. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432-3443
20. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130(6):478-486
21. http://www.emea.europa.eu/humandocs/Humans/EPAR/enbrel/enbrel.htm.
22. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4):253-259
23. Jobanputra P, Barton P, Bryan S, Burls A (2002) The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 6(21):1-110
24. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46(6):1443-1450
25. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675-681
26. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T et al (2004) Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 50(2):353-363
27. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35-45
28. http://www.emea.europa.eu/humandocs/Humans/EPAR/trudexa/trudexa.htm.
29. http://www.emea.europa.eu/humandocs/Humans/EPAR/humira/humira.htm.
30. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63(5):508-516
31. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50(5):1400-1411
32. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26-37
33. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(3):614-624
34. http://www.emea.europa.eu/humandocs/Humans/EPAR/kineret/kineret.htm.
35. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ et al (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63(9):1062-1068
36. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V et al (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93(3):198-208
37. Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H, Houben H, Griffiths B, Edmonds J, Bresnihan B, Boonen A, ven del Linden S (2002) Determination of the minimal clinical important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde, and Larsen/Scott scoring methods by clinical experts and comparison with smallest detectable difference. Arthritis Rheum 46(4):913-920
38. Boers M (2006) Abatacept in rheumatoid arthritis: a new branch on the "biologics" tree. Ann Intern Med 144(12):933-935
39. Boers M (2005) Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in opposition. Arthritis Rheum 52(6):1642-1645
40. Voskuyl AE, Dijkmants BA (2006) Remission and radiographic progression in rheumatoid arthritis. Clin Exp Rheumatol 24[Suppl 43]:37-40
41. Klippel JH (2000) Biologic therapy for rheumatoid arthritis. N Engl J Med 343(22):1640-1641 [Erratum in: N Engl J Med (2001) 344(1):76]